Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
| Revenue (TTM) | $754.04M |
| Gross Profit (TTM) | $412.11M |
| EBITDA | $94.89M |
| Operating Margin | 13.70% |
| Return on Equity | 13.70% |
| Return on Assets | 8.18% |
| Revenue/Share (TTM) | $10.03 |
| Book Value | $8.22 |
| Price-to-Book | 8.06 |
| Price-to-Sales (TTM) | 8.11 |
| EV/Revenue | 5.87 |
| EV/EBITDA | 46.61 |
| Quarterly Earnings Growth (YoY) | 145.50% |
| Quarterly Revenue Growth (YoY) | 55.50% |
| Shares Outstanding | $46.30M |
| Float | $42.20M |
| % Insiders | 3.58% |
| % Institutions | 102.66% |
Volatility is currently expanding
Kiniksa Pharmaceuticals International NASDAQ: KNSA reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the company cited continued expansion in both new and repeat prescribers for the recurrent pericarditis treatment.
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.3 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.23 per share a year ago.
– ARCALYST¨ (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 – – KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing patients – – Conference call and webcast scheduled for 8:30 am ET today –
Despite a volatile market, AOUT, CMPR, NESR, CTO and KNSA are five stocks showing recent price strength.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Let's take a look at four stocks, FLXS, ARKO, KNSA and BSET, with impressive net profit margins for a robust portfolio.
Kiniksa Pharmaceuticals International, plc (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Does Kiniksa Pharmaceuticals International, plc (KNSA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Let's take a look at four stocks, BTSG, KNSA, ATI and VMI, with stellar net profit margins and rising EPS estimates that can help create a winning portfolio.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KNSA and any ticker you trade — then tracks every position and per-strategy win rate.
